单剂人乳头瘤病毒疫苗与未接种或标准三剂及两剂接种方案相比的效力与免疫原性:临床试验证据的系统综述
本系统综述检索1999年1月至2018年8月文献,纳入7项研究,其中6项为三项大型HPV疫苗试验中随机接受两剂或三剂但部分未完成者的嵌套观察性研究,1项为小规模试点研究。结果显示单剂接种者HPV16/18感染频率与多剂无显著差异,且显著低于未接种者,但抗体水平较低;结论支持单剂可能同样有效,但缺乏前瞻性随机试验证据。
要点
- 单剂HPV疫苗接种者HPV16/18感染频率与两剂或三剂接种者无显著差异(所有比较P>0.05)。
- 单剂接种者感染频率显著低于未接种对照(各项感染终点P<0.01)。
- 单剂接种者HPV16/18血清阳性率高,但抗体水平低于两剂或三剂接种者。
核心结论
- 本综述支持以下前提:在健康年轻女性中,单剂HPV疫苗预防HPV感染的效力可能与多剂方案相当。
- 本综述也突显了来自专门设计的前瞻性随机试验的证据匮乏。
- 正在进行的评估单剂HPV疫苗与现行推荐方案相比的效力与免疫原性的临床试验结果有待报告。
研究设计与样本
- 系统综述检索Medline、EMBASE、Global Health Database和Cochrane Central Register of Controlled Trials,检索时间范围为1999年1月至2018年8月。
- 共识别6523条唯一记录,最终纳入7项研究。
- 6项为三项大型HPV疫苗试验中随机接受两剂或三剂但部分参与者未完成既定方案的嵌套观察性研究。
- 1项为小规模试点研究,前瞻性分配参与者接受一剂或不接种疫苗。
主要发现
- 所有接种参与者至接种后7年,HPV16/18感染频率低(例如12个月持续性感染<1%),且不随剂次显著差异(所有情况P>0.05)。
- 单剂接种者感染频率显著低于未接种对照(每项研究中所有感染终点P<0.01)。
- 所有HPV疫苗接种者HPV16/18血清阳性率高(报告该终点的4项研究中有3项为100%),但单剂接种者抗体水平低于两剂或三剂接种者。
临床怎么用
- 原文未据此给出推荐。
- 作者认为单剂HPV疫苗在健康年轻女性中预防HPV感染的效力可能与多剂方案相当。
- 作者指出缺乏来自专门设计的前瞻性随机试验的证据,并提及正在进行的临床试验结果有待报告。
局限性
- 证据主要来自嵌套观察性研究,而非专门设计的前瞻性随机试验。
- 仅有一项小规模试点研究前瞻性分配参与者接受一剂或不接种疫苗。
- 缺乏来自专门设计的前瞻性随机试验的可用证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to systematically review the literature on the efficacy and immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose schedules among vaccine trial participants. METHODS: Medline, EMBASE, Global Health Database and Cochrane Central Register of Controlled Trials were searched for publications and conference abstracts (dated January 1999-August 2018) using MeSH and non-MeSH terms for human papillomavirus AND vaccines AND (immunogenicity OR efficacy/effectiveness) AND dosage. Search results were screened against pre-specified eligibility criteria. Data were extracted from included articles, and a narrative synthesis conducted on efficacy against HPV16/18 infection and humoral immunogenicity. RESULTS: Seven of 6,523 unique records identified were included in the review. Six were nested observational studies of participants randomised to receive two or three doses in three large HPV vaccine trials, in which some participants did not complete their allocated schedules. One small pilot study prospectively allocated participants to receive one or no vaccine dose. Frequency of HPV16/18 infection was low (e.g. <1% for 12-month-persistent infection) in all vaccinated participants up to seven years post vaccination and did not significantly differ by number of doses (p > 0.05 in all cases). Frequency of infection was significantly lower in one-dose recipients compared to unvaccinated controls (p < 0.01 for all infection endpoints in each study). HPV16/18 seropositivity rates were high in all HPV vaccine recipients (100% in three of four studies reporting this endpoint), though antibody levels were lower with one compared to two or three doses. CONCLUSIONS: This review supports the premise that one HPV vaccine dose may be as effective in preventing HPV infection as multi-dose schedules in healthy young women. However, it also highlights the paucity of available evidence from purpose-designed, prospectively-randomised trials. Results from ongoing clinical trials assessing the efficacy and immunogenicity of single-dose HPV vaccination compared to currently-recommended schedules are awaited.
引用
- Whitworth HS, Gallagher KE, Howard N, et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2019. PMID: 31870572. doi:10.1016/j.vaccine.2019.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。